Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
Initial breath analysis predicts individual treatment response to anti-PD-1 therapy at three months.
Non-Small Cell Lung Cancer
Quality of Life Is Underreported Across Phase 3 Lung Cancer Trials
QoL measures either remained unpublished — despite being studied — or were not reported at all.
Insights From the Largest Global Precision Medicine Trial in NSCLC: The National Lung Matrix Trial
Continued molecular stratification in lung cancer appears imminent, and many of the patients in these genetic subgroups may benefit from the use of targeted therapies.
Meta-Analysis Shows No OS Benefit of Prophylactic Cranial Irradiation in Patients With Localized NSCLC
Prophylactic cranial irradiation was determined to be tolerable; few adverse effects were observed in patients with stage III NSCLC receiving this treatment.
Addition of Adoptive Immunotherapy to Chemotherapy May Improve Survival in Certain Patients With Lung Cancer
Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.
Promising Early Results for a “Chemo-Free” Frontline Combination Regimen in Patients With Advanced NSCLC
Treatment-related adverse effects of the sintilimab-anlotinib combination regimen included hand-foot syndrome and hyponatremia.
Using “Real-World” Data to Evaluate the Comparative Effectiveness and Safety of First-Line Chemotherapy Regimens in the Setting of Advanced NSCLC
There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.
Factors Underlying Ethnic Differences in Treatment Toxicity and Response in Advanced NSCLC: A Review
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
Integrative Analysis of Lung Cancer Etiology and Risk: An INTEGRAL Progress Report
One goal of the INTEGRAL initiative is to incorporate validated biomarkers of lung cancer risk into lung cancer CT screening protocols.
Pooled Analysis Shows Triple OS With Nivolumab in Advanced NSCLC
Nivolumab was determined to confer a survival advantage due to a greater duration of patient response compared with docetaxel.
Next post in Lung Cancer
